GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AnaptysBio Inc (NAS:ANAB) » Definitions » Cyclically Adjusted PB Ratio

AnaptysBio (AnaptysBio) Cyclically Adjusted PB Ratio : 2.48 (As of May. 01, 2024)


View and export this data going back to 2017. Start your Free Trial

What is AnaptysBio Cyclically Adjusted PB Ratio?

As of today (2024-05-01), AnaptysBio's current share price is $24.41. AnaptysBio's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $9.86. AnaptysBio's Cyclically Adjusted PB Ratio for today is 2.48.

The historical rank and industry rank for AnaptysBio's Cyclically Adjusted PB Ratio or its related term are showing as below:

ANAB' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.02   Med: 2.34   Max: 2.62
Current: 2.16

During the past years, AnaptysBio's highest Cyclically Adjusted PB Ratio was 2.62. The lowest was 2.02. And the median was 2.34.

ANAB's Cyclically Adjusted PB Ratio is ranked worse than
57.1% of 641 companies
in the Biotechnology industry
Industry Median: 1.74 vs ANAB: 2.16

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

AnaptysBio's adjusted book value per share data for the three months ended in Dec. 2023 was $3.313. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $9.86 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


AnaptysBio Cyclically Adjusted PB Ratio Historical Data

The historical data trend for AnaptysBio's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AnaptysBio Cyclically Adjusted PB Ratio Chart

AnaptysBio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 2.17

AnaptysBio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 2.17

Competitive Comparison of AnaptysBio's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, AnaptysBio's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AnaptysBio's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AnaptysBio's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where AnaptysBio's Cyclically Adjusted PB Ratio falls into.



AnaptysBio Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

AnaptysBio's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=24.41/9.86
=2.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AnaptysBio's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, AnaptysBio's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=3.313/129.4194*129.4194
=3.313

Current CPI (Dec. 2023) = 129.4194.

AnaptysBio Quarterly Data

Book Value per Share CPI Adj_Book
201312 -0.578 98.326 -0.761
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 -2.057 99.070 -2.687
201503 0.000 99.621 0.000
201506 -0.279 100.684 -0.359
201509 -2.131 100.392 -2.747
201512 -2.347 99.792 -3.044
201603 -2.384 100.470 -3.071
201606 -2.210 101.688 -2.813
201609 2.465 101.861 3.132
201612 -2.106 101.863 -2.676
201703 5.438 102.862 6.842
201706 5.381 103.349 6.738
201709 4.945 104.136 6.146
201712 12.928 104.011 16.086
201803 12.366 105.290 15.200
201806 11.860 106.317 14.437
201809 18.680 106.507 22.699
201812 18.066 105.998 22.058
201903 17.335 107.251 20.918
201906 16.581 108.070 19.857
201909 15.532 108.329 18.556
201912 14.860 108.420 17.738
202003 14.685 108.902 17.452
202006 13.979 108.767 16.633
202009 13.174 109.815 15.526
202012 14.503 109.897 17.079
202103 13.956 111.754 16.162
202106 14.061 114.631 15.875
202109 13.973 115.734 15.625
202112 12.892 117.630 14.184
202203 11.738 121.301 12.524
202206 10.779 125.017 11.159
202209 9.791 125.227 10.119
202212 9.192 125.222 9.500
202303 7.073 127.348 7.188
202306 5.595 128.729 5.625
202309 4.530 129.860 4.515
202312 3.313 129.419 3.313

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AnaptysBio  (NAS:ANAB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


AnaptysBio Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of AnaptysBio's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AnaptysBio (AnaptysBio) Business Description

Industry
Traded in Other Exchanges
Address
10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonists. The entity generates revenue from collaborative research and development arrangements.
Executives
Paul F. Lizzul officer: Chief Medical Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Eric J Loumeau officer: General Counsel C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Daniel Faga director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Dennis Mulroy officer: Chief Financial Officer
John A Orwin director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Hamza Suria director, officer: President, CEO C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Oleg Nodelman director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
J. Anthony Ware director C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Marco Londei officer: Chief Medical Officer C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Dominic Piscitelli officer: Chief Financial Officer C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
James N Topper director 550 HAMILTON AVENUE, SUITE 100, PALO ALTO CA 94301